How to Properly Dilute and Store AAV Vectors for Consistent Experimental Results

Adeno-associated virus (AAV) serves as a vital gene delivery vector in modern biomedical research and gene therapy applications. To fully harness its potential, it is critical to adopt standardized and scientifically sound dilution and storage practices that preserve the virus’s long-term stability, infectivity, and biological activity.

The first step is to accurately determine the original titer or concentration of the AAV preparation. This can be achieved using quantitative polymerase chain reaction (qPCR), digital droplet PCR (ddPCR), or optical density-based measurements. Knowing the initial viral genome (vg) titer helps establish a reliable dilution strategy tailored to downstream experimental or therapeutic needs.

When selecting a suitable diluent, phosphate-buffered saline (PBS), HEPES-buffered saline, or other physiologically compatible buffers are commonly used. The diluent should not adversely affect AAV particle stability or alter the capsid conformation. Including 0.001–0.05% Pluronic F-68 or 0.001% Tween-20 is sometimes recommended to minimize viral particle adsorption to tube surfaces, especially for low-concentration samples.

Developing a clear dilution plan is essential to ensure accurate and consistent viral dosing. The required dilution factor depends on the intended application—for example, in vitro transduction assays may require lower titers than in vivo injections. Mix the stock AAV solution and diluent thoroughly but gently to achieve a homogeneous suspension, ensuring each aliquot has an equivalent viral genome concentration.

Accurate labeling and meticulous recordkeeping are necessary to trace each sample’s dilution factor, titer, and preparation date. This enables precise control of viral dosage in future experiments and supports data reproducibility.

The final step is aliquoting and cryopreservation. Dispense the diluted AAV solution into single-use cryovials or low-protein-binding tubes to avoid repeated freeze–thaw cycles, which can degrade viral capsids. Store aliquots at −80 °C or lower in an ultra-low temperature freezer. Periodically verify freezer performance to confirm consistent temperature maintenance. If reduced infectivity or decreased titer is observed after long-term storage, fresh aliquots should be prepared.

By maintaining strict control over dilution and storage conditions, researchers can ensure the consistency, functionality, and reliability of AAV samples. This practice not only enhances experimental reproducibility but also supports robust and scalable development in gene therapy research—where the quality and stability of AAV vectors directly influence therapeutic outcomes.